Company Website:
http://www.auriniapharma.com
VICTORIA, British Columbia -- (Business Wire)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the
“Company”), a clinical stage biopharmaceutical company focused on the
global immunology market, today announced the pricing of its
underwritten public offering of 22,300,000 common shares (the
“Offering”). The shares are being sold at a public offering price of
US$6.75 per share. The gross offering proceeds to the Company from this
Offering are expected to be approximately US$150.5 million, before
deducting underwriting discounts and commissions and other estimated
offering expenses. All of the shares are being offered by the Company.
The Offering is expected to close on or about March 20, 2017, subject to
the satisfaction of customary closing conditions.
Leerink Partners LLC and Cantor Fitzgerald & Co. (collectively, the
“Underwriters”) are acting as joint book-running managers for the
Offering. The Company has granted the Underwriters an option
exercisable, in whole or in part, in the sole discretion of the
Underwriters, to purchase 3,345,000 additional shares, for a period of
up to 30 days.
The Offering is subject to customary closing conditions, including
NASDAQ and TSX approvals. For the purposes of the TSX approval, the
Company intends to rely on the exemption set forth in Section 602.1 of
the TSX Company Manual, which provides that the TSX will not apply its
standards to certain transactions involving eligible inter-listed
issuers on a recognized exchange, such as NASDAQ. The Company intends to
use the net proceeds of the Offering for research and development
activities, including Phase 3 clinical trial activities for lupus
nephritis, and working capital purposes.
The Offering is being made pursuant to a U.S. registration statement on
Form F-10, declared effective by the United States Securities and
Exchange Commission (the “SEC”) on November 5, 2015 (the “Registration
Statement”), and the Company’s existing Canadian short form base shelf
prospectus (the “Base Shelf Prospectus”) dated October 16, 2015. A
preliminary prospectus supplement relating to the Offering has been
filed with the securities commissions in the provinces of British
Columbia, Alberta and Ontario in Canada, and with the SEC in the United
States (the “Preliminary Prospectus”), and a final prospectus supplement
relating to the Offering (together with the Preliminary Prospectus, Base
Shelf Prospectus and the Registration Statement, the “Offering
Documents”) will be filed with the securities commissions in the
provinces of British Columbia, Alberta and Ontario in Canada, and with
the SEC in the United States. The Offering Documents will contain
important detailed information about the securities being offered.
Before you invest, you should read the Offering Documents and the other
documents the Company has filed for more complete information about the
Company and the Offering. Copies of the Offering Documents will be
available for free by visiting the Company’s profiles on the SEDAR
website maintained by the Canadian Securities Administrators at www.sedar.com
or the SEC’s website at www.sec.gov,
as applicable. Alternatively, copies of the prospectus supplement will
be available upon request by contacting Leerink Partners LLC; Attention:
Syndicate Department; One Federal Street; 37th Floor; Boston, MA, 02110,
or by phone at 1-800-808-7525, ext. 6142, or by email at syndicate@leerink.com
or Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Ave., 5th
Floor, New York, New York 10022, or by telephone at 212-829-7122, or by
e-mail at prospectus@cantor.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy securities, nor will there be any sale
of the securities in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to the registration or qualification
under the securities laws of any such jurisdiction.
ABOUT AURINIA
Aurinia is a clinical stage biopharmaceutical company focused on
developing and commercializing therapies to treat targeted patient
populations that are suffering from serious diseases with a high unmet
medical need. The Company is currently developing voclosporin, an
investigational drug, for the treatment of lupus nephritis (LN). The
Company is headquartered in Victoria, British Columbia and focuses its
development efforts globally.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170314005793/en/
Contacts:
Investors:
Aurinia Pharmaceuticals Inc.
Celia Economides
Head
of IR & Communications
ceconomides@auriniapharma.com
or
Media:
Christopher
Hippolyte, 917-826-2664
Christopher.hippolyte@inventivhealth.com
Source: Aurinia Pharmaceuticals Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.